{ "meta": { "data_length": 6, "message": "Statements retrieved successfully", "request_url": "http://api.moalmanac.org/statements?proposition_id=507&agent_id=fda&agent_id=ema", "status": "success", "status_code": 200, "timestamp_elapsed": 0.037616, "timestamp_received": "2026-04-12T07:00:51.800630+00:00Z", "timestamp_returned": "2026-04-12T07:00:51.838246+00:00Z", "trace_id": "55433ecf-5c77-4384-8973-b7e106a3b8e6" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://dev.moalmanac.org", "last_updated": "2026-04-09" }, "data": [ { "id": 591, "type": "Statement", "description": "The U.S. Food and Drug Administration (FDA) granted approval to nivolumab in combination with ipilimumab for the treatment of adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.", "contributions": [ { "id": 4, "type": "Contribution", "agent": { "id": "vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute", "last_updated": null, "url": null }, "description": "The FDA provided regular approval to nivolumab in combination with ipilimumab the treatment of adults and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or DNA mismatch repair deficient (dMMR), metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. However, they split the approval in two indications: as a single agent and still as a combination for patients who have progressed on the previously listed therapies. We added a new indication to cover the combination treatment and updated all statements and propositions accordingly.", "date": "2025-04-30" }, { "id": 0, "type": "Contribution", "agent": { "id": "vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute", "last_updated": null, "url": null }, "description": "Initial access of FDA approvals", "date": "2024-10-30" } ], "reportedIn": [ { "id": "doc:fda.opdivo", "type": "Document", "documentType": "Regulatory approval", "name": "Opdivo (nivolumab) [package insert]. FDA.", "title": null, "aliases": [], "description": "Bristol-Myers Squibb Company. Opdivo (nivolumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf. Revised April 2025. Accessed April 30, 2025.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States.", "extensions": [ { "name": "last_updated", "value": "2026-04-09", "description": "" }, { "name": "url", "value": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "description": "" } ] }, "description": "The organization that published this document." }, { "name": "company", "value": "Bristol-Myers Squibb Company.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Opdivo", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "nivolumab", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2014-12-22", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 125554, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2025-04-11", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "indication": { "id": "ind:fda.opdivo:4", "indication": "OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab.", "initial_approval_date": "2018-07-10", "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125554s063lbl.pdf", "description": "The U.S. Food and Drug Administration (FDA) granted approval to nivolumab in combination with ipilimumab for the treatment of adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.", "raw_biomarkers": "microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)", "raw_cancer_type": "colorectal cancer", "raw_therapeutics": "nivolumab in combination with ipilimumab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": "2025-04-08", "date_accelerated_approval": "2018-07-10", "document": { "id": "doc:fda.opdivo", "type": "Document", "documentType": "Regulatory approval", "name": "Opdivo (nivolumab) [package insert]. FDA.", "title": null, "aliases": [], "description": "Bristol-Myers Squibb Company. Opdivo (nivolumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf. Revised April 2025. Accessed April 30, 2025.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States.", "extensions": [ { "name": "last_updated", "value": "2026-04-09", "description": "" }, { "name": "url", "value": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "description": "" } ] }, "description": "The organization that published this document." }, { "name": "company", "value": "Bristol-Myers Squibb Company.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Opdivo", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "nivolumab", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2014-12-22", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 125554, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2025-04-11", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } }, "proposition": { "id": 507, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [ { "id": 36, "name": "dMMR", "genes": [], "type": "CategoricalVariant", "extensions": [ { "name": "biomarker_type", "value": "Mismatch Repair" }, { "name": "present", "value": true }, { "name": "status", "value": "Deficient" } ] } ], "subjectVariant": {}, "conditionQualifier": { "id": 15, "conceptType": "Disease", "name": "Colorectal Adenocarcinoma", "primaryCoding": { "id": "oncotree:COADREAD", "code": "COADREAD", "name": "Colorectal Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD" ] }, "mappings": [] }, "objectTherapeutic": { "id": 29, "membership_operator": "AND", "therapies": [ { "id": 72, "conceptType": "Drug", "name": "Nivolumab", "primaryCoding": { "id": "ncit:C68814", "code": "C68814", "name": "Nivolumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814" ] }, "mappings": [], "extensions": [ { "name": "therapy_strategy", "value": [ "PD-1/PD-L1 inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ] }, { "id": 71, "conceptType": "Drug", "name": "Ipilimumab", "primaryCoding": { "id": "ncit:C2654", "code": "C2654", "name": "Ipilimumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654" ] }, "mappings": [], "extensions": [ { "name": "therapy_strategy", "value": [ "CTLA-4 inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ] } ] } } }, { "id": 195, "type": "Statement", "description": "The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in combination with nivolumab.", "contributions": [ { "id": 4, "type": "Contribution", "agent": { "id": "vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute", "last_updated": null, "url": null }, "description": "The FDA provided regular approval to nivolumab in combination with ipilimumab the treatment of adults and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or DNA mismatch repair deficient (dMMR), metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. However, they split the approval in two indications: as a single agent and still as a combination for patients who have progressed on the previously listed therapies. We added a new indication to cover the combination treatment and updated all statements and propositions accordingly.", "date": "2025-04-30" }, { "id": 0, "type": "Contribution", "agent": { "id": "vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute", "last_updated": null, "url": null }, "description": "Initial access of FDA approvals", "date": "2024-10-30" } ], "reportedIn": [ { "id": "doc:fda.yervoy", "type": "Document", "documentType": "Regulatory approval", "name": "Yervoy (ipilimumab) [package insert]. FDA.", "title": null, "aliases": [], "description": "Bristol-Myers Squibb Company. Yervoy (ipilimumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf. Revised April 2025. Accessed April 30, 2025.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125377" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States.", "extensions": [ { "name": "last_updated", "value": "2026-04-09", "description": "" }, { "name": "url", "value": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "description": "" } ] }, "description": "The organization that published this document." }, { "name": "company", "value": "Bristol-Myers Squibb Company.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Yervoy", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "ipilimumab", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2011-03-25", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 125377, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2025-04-11", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "indication": { "id": "ind:fda.yervoy:0", "indication": "YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in combination with nivolumab.", "initial_approval_date": "2018-07-10", "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125377s096lbl.pdf", "description": "The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in combination with nivolumab.", "raw_biomarkers": "microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)", "raw_cancer_type": "metastatic colorectal cancer", "raw_therapeutics": "Yervoy (ipilimumab) in combination with nivolumab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": "2025-04-08", "date_accelerated_approval": "2018-07-10", "document": { "id": "doc:fda.yervoy", "type": "Document", "documentType": "Regulatory approval", "name": "Yervoy (ipilimumab) [package insert]. FDA.", "title": null, "aliases": [], "description": "Bristol-Myers Squibb Company. Yervoy (ipilimumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf. Revised April 2025. Accessed April 30, 2025.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125377" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States.", "extensions": [ { "name": "last_updated", "value": "2026-04-09", "description": "" }, { "name": "url", "value": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "description": "" } ] }, "description": "The organization that published this document." }, { "name": "company", "value": "Bristol-Myers Squibb Company.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Yervoy", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "ipilimumab", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2011-03-25", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 125377, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2025-04-11", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } }, "proposition": { "id": 507, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [ { "id": 36, "name": "dMMR", "genes": [], "type": "CategoricalVariant", "extensions": [ { "name": "biomarker_type", "value": "Mismatch Repair" }, { "name": "present", "value": true }, { "name": "status", "value": "Deficient" } ] } ], "subjectVariant": {}, "conditionQualifier": { "id": 15, "conceptType": "Disease", "name": "Colorectal Adenocarcinoma", "primaryCoding": { "id": "oncotree:COADREAD", "code": "COADREAD", "name": "Colorectal Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD" ] }, "mappings": [] }, "objectTherapeutic": { "id": 29, "membership_operator": "AND", "therapies": [ { "id": 72, "conceptType": "Drug", "name": "Nivolumab", "primaryCoding": { "id": "ncit:C68814", "code": "C68814", "name": "Nivolumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814" ] }, "mappings": [], "extensions": [ { "name": "therapy_strategy", "value": [ "PD-1/PD-L1 inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ] }, { "id": 71, "conceptType": "Drug", "name": "Ipilimumab", "primaryCoding": { "id": "ncit:C2654", "code": "C2654", "name": "Ipilimumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654" ] }, "mappings": [], "extensions": [ { "name": "therapy_strategy", "value": [ "CTLA-4 inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ] } ] } } }, { "id": 874, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.", "contributions": [ { "id": 13, "type": "Contribution", "agent": { "id": "vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute", "last_updated": null, "url": null }, "description": "Adding EMA approvals for use to database", "date": "2024-10-20" } ], "reportedIn": [ { "id": "doc:ema.opdivo", "type": "Document", "documentType": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "title": null, "aliases": [], "description": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised June 2025. Accessed September 5, 2025.", "urls": [ "https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo", "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "extensions": [ { "name": "last_updated", "value": "2025-10-01", "description": "" }, { "name": "url", "value": "https://www.ema.europa.eu/en/medicines", "description": "" } ] }, "description": "The organization that published this document." }, { "name": "company", "value": "Bristol-Myers Squibb Pharma EEIG.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Opdivo", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "nivolumab", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2015-07-16", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2025-06-02", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "indication": { "id": "ind:ema.opdivo:3", "indication": "OPDIVO in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.", "initial_approval_date": "2021-07-07", "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/opdivo-h-c-3985-ws-1840-epar-assessment-report-variation_en.pdf", "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.", "raw_biomarkers": null, "raw_cancer_type": "Colorectal cancer", "raw_therapeutics": "Opdivo (nivolumab) in combination with ipilimumab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": { "id": "doc:ema.opdivo", "type": "Document", "documentType": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "title": null, "aliases": [], "description": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised June 2025. Accessed September 5, 2025.", "urls": [ "https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo", "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "extensions": [ { "name": "last_updated", "value": "2025-10-01", "description": "" }, { "name": "url", "value": "https://www.ema.europa.eu/en/medicines", "description": "" } ] }, "description": "The organization that published this document." }, { "name": "company", "value": "Bristol-Myers Squibb Pharma EEIG.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Opdivo", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "nivolumab", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2015-07-16", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2025-06-02", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } }, "proposition": { "id": 507, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [ { "id": 36, "name": "dMMR", "genes": [], "type": "CategoricalVariant", "extensions": [ { "name": "biomarker_type", "value": "Mismatch Repair" }, { "name": "present", "value": true }, { "name": "status", "value": "Deficient" } ] } ], "subjectVariant": {}, "conditionQualifier": { "id": 15, "conceptType": "Disease", "name": "Colorectal Adenocarcinoma", "primaryCoding": { "id": "oncotree:COADREAD", "code": "COADREAD", "name": "Colorectal Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD" ] }, "mappings": [] }, "objectTherapeutic": { "id": 29, "membership_operator": "AND", "therapies": [ { "id": 72, "conceptType": "Drug", "name": "Nivolumab", "primaryCoding": { "id": "ncit:C68814", "code": "C68814", "name": "Nivolumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814" ] }, "mappings": [], "extensions": [ { "name": "therapy_strategy", "value": [ "PD-1/PD-L1 inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ] }, { "id": 71, "conceptType": "Drug", "name": "Ipilimumab", "primaryCoding": { "id": "ncit:C2654", "code": "C2654", "name": "Ipilimumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654" ] }, "mappings": [], "extensions": [ { "name": "therapy_strategy", "value": [ "CTLA-4 inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ] } ] } } }, { "id": 1092, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high colorectal cancer in the following settings: first-line treatment of unresectable or metastatic colorectal cancer; treatment of metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.", "contributions": [ { "id": 22, "type": "Contribution", "agent": { "id": "vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute", "last_updated": null, "url": null }, "description": "On 2025-01-13, the EMA published an EPAR - Assessment report - Variation for Opdivo (nivolumab) for that added an extension indication to nivolumab in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high colorectal cancer in the following settings: first-line treatment of unresectable or metastatic colorectal cancer; treatment of metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.", "date": "2025-09-04" } ], "reportedIn": [ { "id": "doc:ema.opdivo", "type": "Document", "documentType": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "title": null, "aliases": [], "description": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised June 2025. Accessed September 5, 2025.", "urls": [ "https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo", "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "extensions": [ { "name": "last_updated", "value": "2025-10-01", "description": "" }, { "name": "url", "value": "https://www.ema.europa.eu/en/medicines", "description": "" } ] }, "description": "The organization that published this document." }, { "name": "company", "value": "Bristol-Myers Squibb Pharma EEIG.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Opdivo", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "nivolumab", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2015-07-16", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2025-06-02", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "indication": { "id": "ind:ema.opdivo:7", "indication": "OPDIVO in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high colorectal cancer in the following settings: first-line treatment of unresectable or metastatic colorectal cancer; treatment of metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.", "initial_approval_date": "2025-01-13", "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/opdivo-h-c-ws-2672-epar-assessment-report-variation_en.pdf", "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high colorectal cancer in the following settings: first-line treatment of unresectable or metastatic colorectal cancer; treatment of metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.", "raw_biomarkers": "mismatch repair deficient or microsatellite instability-high", "raw_cancer_type": "colorectal cancer", "raw_therapeutics": "Opdivo (nivolumab) in combination with ipilimumab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": { "id": "doc:ema.opdivo", "type": "Document", "documentType": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "title": null, "aliases": [], "description": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised June 2025. Accessed September 5, 2025.", "urls": [ "https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo", "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "extensions": [ { "name": "last_updated", "value": "2025-10-01", "description": "" }, { "name": "url", "value": "https://www.ema.europa.eu/en/medicines", "description": "" } ] }, "description": "The organization that published this document." }, { "name": "company", "value": "Bristol-Myers Squibb Pharma EEIG.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Opdivo", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "nivolumab", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2015-07-16", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2025-06-02", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } }, "proposition": { "id": 507, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [ { "id": 36, "name": "dMMR", "genes": [], "type": "CategoricalVariant", "extensions": [ { "name": "biomarker_type", "value": "Mismatch Repair" }, { "name": "present", "value": true }, { "name": "status", "value": "Deficient" } ] } ], "subjectVariant": {}, "conditionQualifier": { "id": 15, "conceptType": "Disease", "name": "Colorectal Adenocarcinoma", "primaryCoding": { "id": "oncotree:COADREAD", "code": "COADREAD", "name": "Colorectal Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD" ] }, "mappings": [] }, "objectTherapeutic": { "id": 29, "membership_operator": "AND", "therapies": [ { "id": 72, "conceptType": "Drug", "name": "Nivolumab", "primaryCoding": { "id": "ncit:C68814", "code": "C68814", "name": "Nivolumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814" ] }, "mappings": [], "extensions": [ { "name": "therapy_strategy", "value": [ "PD-1/PD-L1 inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ] }, { "id": 71, "conceptType": "Drug", "name": "Ipilimumab", "primaryCoding": { "id": "ncit:C2654", "code": "C2654", "name": "Ipilimumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654" ] }, "mappings": [], "extensions": [ { "name": "therapy_strategy", "value": [ "CTLA-4 inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ] } ] } } }, { "id": 1025, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.", "contributions": [ { "id": 13, "type": "Contribution", "agent": { "id": "vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute", "last_updated": null, "url": null }, "description": "Adding EMA approvals for use to database", "date": "2024-10-20" } ], "reportedIn": [ { "id": "doc:ema.yervoy", "type": "Document", "documentType": "Regulatory approval", "name": "Yervoy (ipilimumab) [product information]. EMA.", "title": null, "aliases": [], "description": "Bristol-Myers Squibb Pharma EEIG. Yervoy (ipilimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf. Revised March 2025. Accessed September 5, 2025.", "urls": [ "https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy", "https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "extensions": [ { "name": "last_updated", "value": "2025-10-01", "description": "" }, { "name": "url", "value": "https://www.ema.europa.eu/en/medicines", "description": "" } ] }, "description": "The organization that published this document." }, { "name": "company", "value": "Bristol-Myers Squibb Pharma EEIG.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Yervoy", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "ipilimumab", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2011-07-25", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2025-03-17", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "indication": { "id": "ind:ema.yervoy:1", "indication": "YERVOY in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.", "initial_approval_date": "2021-06-29", "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/yervoy-h-c-002213-ws-1840-epar-assessment-report-variation_en.pdf", "description": "The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.", "raw_biomarkers": null, "raw_cancer_type": "Colorectal cancer", "raw_therapeutics": "Yervoy (ipilimumab) in combination with nivolumab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": { "id": "doc:ema.yervoy", "type": "Document", "documentType": "Regulatory approval", "name": "Yervoy (ipilimumab) [product information]. EMA.", "title": null, "aliases": [], "description": "Bristol-Myers Squibb Pharma EEIG. Yervoy (ipilimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf. Revised March 2025. Accessed September 5, 2025.", "urls": [ "https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy", "https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "extensions": [ { "name": "last_updated", "value": "2025-10-01", "description": "" }, { "name": "url", "value": "https://www.ema.europa.eu/en/medicines", "description": "" } ] }, "description": "The organization that published this document." }, { "name": "company", "value": "Bristol-Myers Squibb Pharma EEIG.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Yervoy", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "ipilimumab", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2011-07-25", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2025-03-17", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } }, "proposition": { "id": 507, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [ { "id": 36, "name": "dMMR", "genes": [], "type": "CategoricalVariant", "extensions": [ { "name": "biomarker_type", "value": "Mismatch Repair" }, { "name": "present", "value": true }, { "name": "status", "value": "Deficient" } ] } ], "subjectVariant": {}, "conditionQualifier": { "id": 15, "conceptType": "Disease", "name": "Colorectal Adenocarcinoma", "primaryCoding": { "id": "oncotree:COADREAD", "code": "COADREAD", "name": "Colorectal Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD" ] }, "mappings": [] }, "objectTherapeutic": { "id": 29, "membership_operator": "AND", "therapies": [ { "id": 72, "conceptType": "Drug", "name": "Nivolumab", "primaryCoding": { "id": "ncit:C68814", "code": "C68814", "name": "Nivolumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814" ] }, "mappings": [], "extensions": [ { "name": "therapy_strategy", "value": [ "PD-1/PD-L1 inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ] }, { "id": 71, "conceptType": "Drug", "name": "Ipilimumab", "primaryCoding": { "id": "ncit:C2654", "code": "C2654", "name": "Ipilimumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654" ] }, "mappings": [], "extensions": [ { "name": "therapy_strategy", "value": [ "CTLA-4 inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ] } ] } } }, { "id": 1112, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab for the first-line treatment of adult patients with mismatch repair deficient or microsatellite instability-high unresectable or metastatic colorectal cancer.", "contributions": [ { "id": 29, "type": "Contribution", "agent": { "id": "vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute", "last_updated": null, "url": null }, "description": "On 2025-01-13, the EMA published an EPAR - Assessment report - Variation for Yervoy (ipilimumab) that added an extension indication to ipilimumab in combination with nivolumab for the first-line treatment of adult patients with mismatch repair deficient or microsatellite instability-high unresectable or metastatic colorectal cancer.", "date": "2025-09-05" } ], "reportedIn": [ { "id": "doc:ema.yervoy", "type": "Document", "documentType": "Regulatory approval", "name": "Yervoy (ipilimumab) [product information]. EMA.", "title": null, "aliases": [], "description": "Bristol-Myers Squibb Pharma EEIG. Yervoy (ipilimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf. Revised March 2025. Accessed September 5, 2025.", "urls": [ "https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy", "https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "extensions": [ { "name": "last_updated", "value": "2025-10-01", "description": "" }, { "name": "url", "value": "https://www.ema.europa.eu/en/medicines", "description": "" } ] }, "description": "The organization that published this document." }, { "name": "company", "value": "Bristol-Myers Squibb Pharma EEIG.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Yervoy", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "ipilimumab", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2011-07-25", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2025-03-17", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "indication": { "id": "ind:ema.yervoy:3", "indication": "YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with mismatch repair deficient or microsatellite instability-high unresectable or metastatic colorectal cancer.", "initial_approval_date": "2025-01-13", "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/yervoy-h-c-ws2672-epar-assessment-report-variation_en.pdf", "description": "The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab for the first-line treatment of adult patients with mismatch repair deficient or microsatellite instability-high unresectable or metastatic colorectal cancer.", "raw_biomarkers": "mismatch repair deficient or microsatellite instability-high", "raw_cancer_type": "colorectal cancer", "raw_therapeutics": "Yervoy (ipilimumab) in combination with nivolumab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": { "id": "doc:ema.yervoy", "type": "Document", "documentType": "Regulatory approval", "name": "Yervoy (ipilimumab) [product information]. EMA.", "title": null, "aliases": [], "description": "Bristol-Myers Squibb Pharma EEIG. Yervoy (ipilimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf. Revised March 2025. Accessed September 5, 2025.", "urls": [ "https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy", "https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "extensions": [ { "name": "last_updated", "value": "2025-10-01", "description": "" }, { "name": "url", "value": "https://www.ema.europa.eu/en/medicines", "description": "" } ] }, "description": "The organization that published this document." }, { "name": "company", "value": "Bristol-Myers Squibb Pharma EEIG.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Yervoy", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "ipilimumab", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2011-07-25", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2025-03-17", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } }, "proposition": { "id": 507, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [ { "id": 36, "name": "dMMR", "genes": [], "type": "CategoricalVariant", "extensions": [ { "name": "biomarker_type", "value": "Mismatch Repair" }, { "name": "present", "value": true }, { "name": "status", "value": "Deficient" } ] } ], "subjectVariant": {}, "conditionQualifier": { "id": 15, "conceptType": "Disease", "name": "Colorectal Adenocarcinoma", "primaryCoding": { "id": "oncotree:COADREAD", "code": "COADREAD", "name": "Colorectal Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD" ] }, "mappings": [] }, "objectTherapeutic": { "id": 29, "membership_operator": "AND", "therapies": [ { "id": 72, "conceptType": "Drug", "name": "Nivolumab", "primaryCoding": { "id": "ncit:C68814", "code": "C68814", "name": "Nivolumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814" ] }, "mappings": [], "extensions": [ { "name": "therapy_strategy", "value": [ "PD-1/PD-L1 inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ] }, { "id": 71, "conceptType": "Drug", "name": "Ipilimumab", "primaryCoding": { "id": "ncit:C2654", "code": "C2654", "name": "Ipilimumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654" ] }, "mappings": [], "extensions": [ { "name": "therapy_strategy", "value": [ "CTLA-4 inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ] } ] } } } ] }